- Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
- Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
- Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
- Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
- Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
More ▼
Key statistics
As of last trade Vera Therapeutics Inc (VERA:NMQ) traded at 39.92, -21.39% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.92 |
---|---|
High | 39.92 |
Low | 39.92 |
Bid | 39.77 |
Offer | 40.48 |
Previous close | 40.27 |
Average volume | 831.60k |
---|---|
Shares outstanding | 54.70m |
Free float | 50.37m |
P/E (TTM) | -- |
Market cap | 2.08bn USD |
EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 14:30 BST.
More ▼